898538-71-1

Upstream product

• 1000369-05-0 4-(benzyloxy)-5-bromo-N-methoxy-N-methylbenzamide 
• 101093-56-5 4-benzyloxy-2-methyl-benzaldehyde 
• 957774-00-4 1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone 
• 1000369-04-9 4-(benzyloxy)-5-bromo-2-methylbenzoyl chloride 
• 608119-82-0 1-(4-(benzyloxy)-2-methylphenyl)ethanone 
• 875-59-2 4'-hydroxy-2'methylacetophenone 
• 578-39-2 4-hydroxy-2-methylbenzoic acid 
• 100-39-0 benzyl bromide 
• 41438-18-0 4-hydroxy-2-methyl-benzaldehyde 

Downstream Products

• 957773-99-8 2-(4-(benzyloxy)-5-bromo-2-methylphenyl)-1,3-dioxolane 
• 957774-13-9 [4-(benzyloxy)-5-bromo-2-methylphenyl][4-[2-(methoxymethoxy)ethyl]phenyl]methanol 
• 1033723-28-2 (4-(benzyloxy)-5-bromo-2-methylphenyl)(4-ethylphenyl)methanol 

Relevant academic research and scientific papers

5,5-DIFLUORO- AND 5-FLUORO-5-METHYL-C-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS

The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

The design and synthesis of a novel class of low-absorbable SGLT1 inhibitors are described. To achieve low absorption in the new series, we performed an optimization study based on a strategy to increase TPSA. Fortunately, the optimization of an aglycon m

C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF

C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of th

DUAL SGLT1/SGLT2 INHIBITORS

The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.

1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

C-PHENYL GLYCITOL COMPOUND

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is NHC(= NH)NH2 or -NHCON(RB)RC, n is not 1, Z is -CONHRA, -NHC(=NH)NH2 or -NHCON(RB)RC, Formula (A) or Formula (B).